Positive Phase 2 Results for Edasalonexant in DMD Support Phase 3 Study

Catabasis’s small molecule NF-kB inhibitor showed promise in phase 2, and the phase 3 PolarisDMD study (NCT03703882) of edasalonexant is fully enrolled and expected to read out in late 2020.

Source link

Related posts

Spotlight on the December 4 issue


Obesity Drug Belviq Is Heart Safe in Cardiovascular Outcome Study


New tech for multiple sclerosis diagnosis and treatment


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World